

Gene Therapy Market by Type (Gene silencing, Gene augmentation), Vector (Viral (Retroviral, AAV), Non-viral (Oligonucleotide)), Therapeutic Area (Neurology, Oncology), Delivery Method (In-vivo, Ex-vivo), RoA (Intravenous) & Region - Global Forecast to 2028

Market Report | 2023-10-30 | 276 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The gene therapy market is expected to reach USD 23.9 billion by 2028 from USD 9.0 billion in 2023, at a CAGR of 21.4% during the forecast period. The key factors driving the growth of the gene therapy market include increasing initiatives related to genomic research, and increasing number of regulatory approvals for gene therapy products. Moreover, growing demand for cell and gene therapies is an opportunity area for this market.

The gene therapy market has been segmented based on type, vector, therapeutic area, delivery method, route of administration and region.

"By therapeutic area, oncology segment accounted for the second largest share of the gene therapy market"

Based on type, the gene therapy market is categorized into neurology, oncology, hepatology, and other therapeutic areas.. In 2022, oncology accounted for the highest growth rate owing to factors such as The rising demand for targeted therapies (including gene therapy) against cancer, increasing cancer prevalence are the major factors driving the growth of this segment.

"By delivery method, the in vivo segment accounted for the largest share in the gene therapy market"

Based on end user, the gene therapy market is segmented into the gene therapy market is segmented into in vivo and ex vivo. In 2022, the in vivo segment accounted for a largest share of the gene therapy market. Growth in this market segment can be attributed to availability of many in vivo gene therapy products commercially and focus of research and development on this delivery method.

"North America: the largest share of the gene therapy market"

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

North America accounted for the largest share of the gene therapy market. The large share of the North America region can be attributed to major factors such as presence of technologically advanced infrastructure in healthcare settings offering gene therapies, and easy accessibility to advanced therapeutics among others. Besides, the region has a well established healthcare system which further supports the growth of this market. Also, presence of some of the key players in the market is another key factor. Some examples of these players include Novartis AG (Switzerland), Biogen Inc. (US), Gilead Sciences, Inc. (US), Bristol-Myers Squibb (US), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US) among others.

"Europe: The fastest-growing region in the gene therapy market."

The Europe gene therapy market is projected to grow at the highest CAGR during the forecast period. This is attributed to one of the major factors including the growing initiatives for advancements of gene therapies, increasing prevalence of chronic diseases and support offered by the government organizations for developing advanced targeted therapies.

The primary interviews conducted for this report can be categorized as follows:

-□By Respondent: Supply Side- 70% and Demand Side 30%

-□By Designation: Managers - 45%, Directors- 30%, and Executives - 25%

-□By Country: North America- 25%, Europe- 25%, Asia Pacific- 40%, Latin America- 5%, and Middle East- 3% & Africa- 2%

Prominent Players

-□Novartis AG (Switzerland)

-□Biogen Inc. (US)

-□Gilead Sciences, Inc. (US)

-□Bristol-Myers Squibb (US)

-□Alnylam Pharmaceuticals, Inc. (US)

-□Sarepta Therapeutics, Inc. (US)

-□Amgen, Inc. (US)

-□Orchard Therapeutics Plc (UK)

-□F. Hoffmann-La Roche Ltd. (Switzerland)

-□Jazz Pharmaceuticals Plc (Ireland)

-□uniQure N.V. (Netherlands)

-□Johnson & Johnson (US)

-□Bluebird Bio, Inc. (US)

-□BioMarin Pharmaceutical Inc. (US)

-□Krystal Biotech, Inc. (US)

-□Shanghai Sunway Biotech Co. Ltd. (China)

-□SIBIONO GeneTech Co. Ltd. (China)

-□Ferring B.V. (Switzerland)

-□Vertex Pharmaceuticals Incorporated (US)

-□Pfizer, Inc. (US)

-□Sangamo Therapeutics, Inc. (US)

-□REGENXBIO (US)

-□Ultragenyx Pharmaceutical Inc. (US)

-□MeiraGTx Holdings Plc (US)

-□AnGes, Inc. (Japan)

Research Coverage:

This report provides a detailed picture of the gene therapy market. It aims at estimating the size and future growth potential of the market across different segments, such as the type, indication, end user and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the gene therapy market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

The report provide insights on the following pointers"

-□Analysis of key drivers (growth in regulatory approvals for gene therapy products), opportunities (cell and gene therapy demand), restraint (budget constraints) and challenges (challenges associated with supply chain) influencing the growth of the gene therapy market.

-□Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the gene therapy market.

-□Market Development: Comprehensive information about lucrative markets- the report analyses the gene therapy market across varied regions.

-□Market Diversification: Exhaustive information about new products and service, untapped geographies, recent developments, and investments in the gene therapy market.

-□Analysis of clinical pipeline data and data on products estimated to be launched during the forecast period.

-□Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like Novartis AG (Switzerland), Biogen Inc. (US), Gilead Sciences, Inc. (US), Bristol-Myers Squibb (US), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), Amgen, Inc. (US), Orchard Therapeutics Plc (UK), F. Hoffmann-La Roche Ltd. (Switzerland), among others in the gene therapy market.

Table of Contents:

1□INTRODUCTION□40

1.1□STUDY OBJECTIVES□40

1.2□MARKET DEFINITION□40

1.2.1□INCLUSIONS & EXCLUSIONS□41

1.3□MARKET SCOPE□41

1.3.1□MARKETS COVERED□41

FIGURE 1□GENE THERAPY MARKET SEGMENTATION□41

1.3.2□YEARS CONSIDERED□42

1.4□CURRENCY CONSIDERED□42

1.5□LIMITATIONS□42

1.6□STAKEHOLDERS□43

1.7□SUMMARY OF CHANGES□43

1.7.1□RECESSION IMPACT□43

2□RESEARCH METHODOLOGY□44

2.1□RESEARCH DATA□44

FIGURE 2□RESEARCH DESIGN□44

2.1.1□SECONDARY DATA□45

2.1.2□PRIMARY DATA□46

FIGURE 3□GENE THERAPY MARKET: BREAKDOWN OF PRIMARIES□46

2.2□MARKET SIZE ESTIMATION OF GENE THERAPY MARKET□47

FIGURE 4□MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS□47

FIGURE 5□MARKET SIZE ESTIMATION FOR GENE THERAPY MARKET: REVENUE SHARE ANALYSIS□48

2.2.1□INSIGHTS FROM PRIMARIES□49

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

FIGURE 6 □ MARKET VALIDATION FROM PRIMARY EXPERTS □ 49

FIGURE 7 □ MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH □ 50

2.3 □ GROWTH FORECAST □ 51

FIGURE 8 □ GENE THERAPY MARKET: CAGR PROJECTIONS □ 51

FIGURE 9 □ GENE THERAPY MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES □ 52

2.4 □ MARKET BREAKDOWN AND DATA TRIANGULATION □ 53

FIGURE 10 □ DATA TRIANGULATION METHODOLOGY □ 53

2.5 □ RESEARCH ASSUMPTIONS □ 54

2.6 □ RISK ANALYSIS □ 54

2.7 □ RECESSION IMPACT ANALYSIS □ 54

TABLE 1 □ GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH) □ 54

3 □ EXECUTIVE SUMMARY □ 56

FIGURE 11 □ GENE THERAPY MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) □ 56

FIGURE 12 □ GENE THERAPY MARKET, BY VECTOR, 2023 VS. 2028 (USD MILLION) □ 57

FIGURE 13 □ GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION) □ 57

FIGURE 14 □ GENE THERAPY MARKET, BY DELIVERY METHOD, 2023 VS. 2028 (USD MILLION) □ 58

FIGURE 15 □ GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD MILLION) □ 58

FIGURE 16 □ GEOGRAPHICAL SNAPSHOT OF GENE THERAPY MARKET □ 59

4 □ PREMIUM INSIGHTS □ 60

4.1 □ GENE THERAPY MARKET OVERVIEW □ 60

FIGURE 17 □ INCREASING INVESTMENTS IN GENE THERAPY RESEARCH TO DRIVE GROWTH IN GENE THERAPY MARKET □ 60

4.2 □ NORTH AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA & COUNTRY (2022) □ 61

FIGURE 18 □ NEUROLOGY ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022 □ 61

4.3 □ GENE THERAPY MARKET, BY VECTOR, 2022 □ 62

FIGURE 19 □ VIRAL VECTORS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD □ 62

4.4 □ GENE THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES □ 62

FIGURE 20 □ GERMANY TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD □ 62

5 □ MARKET OVERVIEW □ 63

5.1 □ INTRODUCTION □ 63

5.2 □ MARKET DYNAMICS □ 63

FIGURE 21 □ GENE THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES □ 63

5.2.1 □ DRIVERS □ 64

5.2.1.1 □ Increasing regulatory approvals for gene therapy products □ 64

TABLE 2 □ LIST OF KEY PRODUCT APPROVALS IN GENE THERAPY MARKET, 2021-2023 □ 64

5.2.1.2 □ Increasing investments in gene therapy research □ 65

5.2.1.3 □ Growing technological advancements □ 66

TABLE 3 □ LIST OF ADVANCED PLATFORMS LAUNCHED IN GENE THERAPY MARKET, 2022-2023 □ 66

5.2.1.4 □ Rising prevalence of genetic disorders and cancer □ 67

5.2.2 □ RESTRAINTS □ 67

5.2.2.1 □ High cost of gene therapy products □ 67

TABLE 4 □ COST OF GENE THERAPY PRODUCTS □ 68

5.2.3 □ OPPORTUNITIES □ 69

5.2.3.1 □ Rising demand for cell & gene therapies □ 69

5.2.3.2 □ Increasing focus on precision medicine □ 69

5.2.4 □ CHALLENGES □ 70

5.2.4.1 □ Complex manufacturing process □ 70

5.2.4.2 □ Short shelf life and supply chain challenges □ 70

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.3	PORTER'S FIVE FORCES ANALYSIS	71
TABLE 5	GENE THERAPY MARKET: PORTER'S FIVE FORCES ANALYSIS	71
5.3.1	THREAT OF NEW ENTRANTS	71
5.3.2	THREAT OF SUBSTITUTES	71
5.3.3	BARGAINING POWER OF SUPPLIERS	71
5.3.4	BARGAINING POWER OF BUYERS	72
5.3.5	INTENSITY OF COMPETITIVE RIVALRY	72
5.4	TECHNOLOGY ANALYSIS	72
5.5	VALUE CHAIN ANALYSIS	73
FIGURE 22	GENE THERAPY MARKET: VALUE CHAIN	73
5.6	ECOSYSTEM ANALYSIS	74
FIGURE 23	GENE THERAPY MARKET: ECOSYSTEM MAP	74
5.7	PATENT ANALYSIS	75
FIGURE 24	PATENT APPLICATIONS FOR GENE THERAPY PRODUCTS, JANUARY 2012-SEPTEMBER 2023	75
TABLE 6	GENE THERAPY MARKET: INDICATIVE LIST OF PATENTS	76
5.8	PIPELINE ANALYSIS	76
TABLE 7	GENE THERAPY PRODUCTS IN CLINICAL PIPELINE	76
5.9	SUPPLY CHAIN ANALYSIS	78
FIGURE 25	GENE THERAPY MARKET: SUPPLY CHAIN ANALYSIS	79
TABLE 8	SUPPLY CHAIN ECOSYSTEM	80
5.10	REGULATORY LANDSCAPE	81
5.10.1	REGULATORY ANALYSIS	81
5.10.2	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION	81
TABLE 9	NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	81
TABLE 10	EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	82
TABLE 11	ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	82
TABLE 12	REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	83
5.11	PRICING ANALYSIS	83
5.11.1	AVERAGE SELLING PRICE TREND OF KEY PLAYERS	83
TABLE 13	AVERAGE SELLING PRICE OF GENE THERAPY PRODUCTS	83
TABLE 14	AVERAGE SELLING PRICE OF GENE THERAPY PRODUCTS, BY DELIVERY METHOD	84
5.12	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	84
5.13	KEY CONFERENCES & EVENTS	85
TABLE 15	GENE THERAPY MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2023-2024)	85
5.14	KEY STAKEHOLDERS & BUYING CRITERIA	86
5.14.1	KEY STAKEHOLDERS ON BUYING PROCESS	86
FIGURE 26	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR GENE THERAPY PRODUCTS IN HOSPITALS AND CLINICS	86
5.14.2	BUYING CRITERIA FOR GENE THERAPY MARKET	86
FIGURE 27	KEY BUYING CRITERIA FOR HOSPITALS AND CLINICS	86
6	GENE THERAPY MARKET, BY TYPE	87
6.1	INTRODUCTION	88
TABLE 16	GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)	88
6.2	GENE SILENCING	88
6.2.1	HIGH FLEXIBILITY AND PRECISION OFFERED BY GENE SILENCING THERAPIES TO SUPPORT GROWTH	88
TABLE 17	GENE SILENCING THERAPY MARKET, BY REGION, 2021-2028 (USD MILLION)	89
TABLE 18	NORTH AMERICA: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	89
TABLE 19	EUROPE: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	89

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 20 ASIA PACIFIC: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 90

TABLE 21 LATIN AMERICA: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 90

6.3 CELL REPLACEMENT 90

6.3.1 LONG-TERM EFFECTS OF CELL REPLACEMENT THERAPY TO BOOST ADOPTION 90

TABLE 22 CELL REPLACEMENT THERAPY MARKET, BY REGION, 2021-2028 (USD MILLION) 91

TABLE 23 NORTH AMERICA: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 91

TABLE 24 EUROPE: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 92

TABLE 25 ASIA PACIFIC: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 92

TABLE 26 LATIN AMERICA: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 92

6.4 GENE AUGMENTATION 93

6.4.1 GROWING USE OF GENE AUGMENTATION THERAPY AGAINST MONOGENIC DISORDERS TO FAVOR MARKET GROWTH 93

TABLE 27 GENE AUGMENTATION THERAPY MARKET, BY REGION, 2021-2028 (USD MILLION) 93

TABLE 28 NORTH AMERICA: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 94

TABLE 29 EUROPE: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 94

TABLE 30 ASIA PACIFIC: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 94

TABLE 31 LATIN AMERICA: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 95

6.5 OTHER THERAPIES 95

7 GENE THERAPY MARKET, BY VECTOR 96

7.1 INTRODUCTION 97

TABLE 32 GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION) 97

7.2 VIRAL VECTORS 97

TABLE 33 GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 98

TABLE 34 GENE THERAPY MARKET FOR VIRAL VECTORS, BY REGION, 2021-2028 (USD MILLION) 98

TABLE 35 NORTH AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) 98

TABLE 36 EUROPE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) 99

TABLE 37 ASIA PACIFIC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) 99

TABLE 38 LATIN AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) 99

7.2.1 RETROVIRAL VECTORS 100

TABLE 39 GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 100

TABLE 40 GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY REGION, 2021-2028 (USD MILLION) 100

TABLE 41 NORTH AMERICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) 101

TABLE 42 EUROPE: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) 101

TABLE 43 ASIA PACIFIC: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) 101

TABLE 44 LATIN AMERICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) 102

7.2.1.1 Gamma retroviral vectors 102

7.2.1.1.1 Availability of wide range of gamma-retroviral vectors to support market growth 102

TABLE 45 GENE THERAPY MARKET FOR GAMMA RETROVIRAL VECTORS, BY REGION, 2021-2028 (USD MILLION) 102

TABLE 46 NORTH AMERICA: GENE THERAPY MARKET FOR GAMMA RETROVIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) 103

TABLE 47 EUROPE: GENE THERAPY MARKET FOR GAMMA RETROVIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) 103

TABLE 48 ASIA PACIFIC: GENE THERAPY MARKET FOR GAMMA RETROVIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) 103

TABLE 49 LATIN AMERICA: GENE THERAPY MARKET FOR GAMMA RETROVIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) 104

7.2.1.2 Lentiviral vectors 104

7.2.1.2.1 North America to dominate lentiviral vectors market 104

TABLE 50 GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY REGION, 2021-2028 (USD MILLION) 105

TABLE 51 NORTH AMERICA: GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) 105

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 52 □ EUROPE: GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) □ 106

TABLE 53 □ ASIA PACIFIC: GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) □ 106

TABLE 54 □ LATIN AMERICA: GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) □ 106

7.2.2 □ ADENO-ASSOCIATED VIRAL VECTORS □ 107

7.2.2.1 □ Growing clinical pipeline of adeno-associated viral vectors to drive growth □ 107

TABLE 55 □ GENE THERAPY MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY REGION, 2021-2028 (USD MILLION) □ 107

TABLE 56 □ NORTH AMERICA: GENE THERAPY MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) □ 108

TABLE 57 □ EUROPE: GENE THERAPY MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) □ 108

TABLE 58 □ ASIA PACIFIC: GENE THERAPY MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) □ 108

TABLE 59 □ LATIN AMERICA: GENE THERAPY MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) □ 109

7.2.3 □ OTHER VIRAL VECTORS □ 109

TABLE 60 □ GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY REGION, 2021-2028 (USD MILLION) □ 109

TABLE 61 □ NORTH AMERICA: GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) □ 110

TABLE 62 □ EUROPE: GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) □ 110

TABLE 63 □ ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) □ 110

TABLE 64 □ LATIN AMERICA: GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) □ 111

7.3 □ NON-VIRAL VECTORS □ 111

TABLE 65 □ GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) □ 111

TABLE 66 □ GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY REGION, 2021-2028 (USD MILLION) □ 112

TABLE 67 □ NORTH AMERICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) □ 112

TABLE 68 □ EUROPE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) □ 113

TABLE 69 □ ASIA PACIFIC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) □ 113

TABLE 70 □ LATIN AMERICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) □ 113

7.3.1 □ OLIGONUCLEOTIDES □ 114

7.3.1.1 □ Oligonucleotides to account for largest share of non-viral vectors market □ 114

TABLE 71 □ GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY REGION, 2021-2028 (USD MILLION) □ 114

TABLE 72 □ NORTH AMERICA: GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY COUNTRY, 2021-2028 (USD MILLION) □ 114

TABLE 73 □ EUROPE: GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY COUNTRY, 2021-2028 (USD MILLION) □ 115

TABLE 74 □ ASIA PACIFIC: GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY COUNTRY, 2021-2028 (USD MILLION) □ 115

TABLE 75 □ LATIN AMERICA: GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY COUNTRY, 2021-2028 (USD MILLION) □ 115

7.3.2 □ OTHER NON-VIRAL VECTORS □ 116

TABLE 76 □ GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY REGION, 2021-2028 (USD MILLION) □ 116

TABLE 77 □ NORTH AMERICA: GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) □ 116

TABLE 78 □ EUROPE: GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) □ 117

TABLE 79 □ ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) □ 117

TABLE 80 □ LATIN AMERICA: GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION) □ 117

8 □ GENE THERAPY MARKET, BY THERAPEUTIC AREA □ 118

8.1 □ INTRODUCTION □ 119

TABLE 81 □ GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) □ 119

8.2 □ NEUROLOGY □ 119

8.2.1 □ GROWING NUMBER OF GENE THERAPY PRODUCTS APPROVED FOR NEUROLOGICAL DISEASE TREATMENT TO DRIVE MARKET GROWTH □ 119

TABLE 82 □ GENE THERAPY MARKET FOR NEUROLOGY, BY REGION, 2021-2028 (USD MILLION) □ 120

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 83 □ NORTH AMERICA: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □ 120

TABLE 84 □ EUROPE: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □ 121

TABLE 85 □ ASIA PACIFIC: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □ 121

TABLE 86 □ LATIN AMERICA: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □ 121

8.3 □ ONCOLOGY □ 122

8.3.1 □ GROWING DEMAND FOR TARGETED THERAPIES AGAINST CANCERS TO DRIVE MARKET GROWTH □ 122

TABLE 87 □ PIPELINE PRODUCTS FOR ONCOLOGY APPLICATIONS □ 122

TABLE 88 □ NUMBER OF NEW CANCER CASES, BY TYPE, 2020 VS. 2040 □ 123

TABLE 89 □ GENE THERAPY MARKET FOR ONCOLOGY, BY REGION, 2021-2028 (USD MILLION) □ 124

TABLE 90 □ NORTH AMERICA: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □ 124

TABLE 91 □ EUROPE: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □ 125

TABLE 92 □ ASIA PACIFIC: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □ 125

TABLE 93 □ LATIN AMERICA: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □ 125

8.4 □ HEPATOLOGY □ 126

8.4.1 □ GROWING R&D ACTIVITIES FOR LIVER CONDITIONS TO SUPPORT GROWTH □ 126

TABLE 94 □ GENE THERAPY MARKET FOR HEPATOLOGY, BY REGION, 2021-2028 (USD MILLION) □ 126

TABLE 95 □ NORTH AMERICA: GENE THERAPY MARKET FOR HEPATOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □ 126

TABLE 96 □ EUROPE: GENE THERAPY MARKET FOR HEPATOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □ 127

TABLE 97 □ ASIA PACIFIC: GENE THERAPY MARKET FOR HEPATOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □ 127

TABLE 98 □ LATIN AMERICA: GENE THERAPY MARKET FOR HEPATOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □ 127

8.5 □ OTHER THERAPEUTIC AREAS □ 128

TABLE 99 □ GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021-2028 (USD MILLION) □ 128

TABLE 100 □ NORTH AMERICA: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION) □ 128

TABLE 101 □ EUROPE: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION) □ 129

TABLE 102 □ ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION) □ 129

TABLE 103 □ LATIN AMERICA: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION) □ 129

9 □ GENE THERAPY MARKET, BY DELIVERY METHOD □ 130

9.1 □ INTRODUCTION □ 131

TABLE 104 □ GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION) □ 131

9.2 □ IN VIVO □ 131

9.2.1 □ IN VIVO DELIVERY METHOD TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD □ 131

TABLE 105 □ COMMERCIALIZED AND PIPELINE IN VIVO-BASED GENE THERAPY PRODUCTS □ 132

TABLE 106 □ IN VIVO GENE THERAPY MARKET, BY REGION, 2021-2028 (USD MILLION) □ 132

TABLE 107 □ NORTH AMERICA: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 133

TABLE 108 □ EUROPE: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 133

TABLE 109 □ ASIA PACIFIC: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 133

TABLE 110 □ LATIN AMERICA: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 134

9.3 □ EX VIVO □ 134

9.3.1 □ GROWING FOCUS ON ONCOLOGY BY MARKET PLAYERS TO SUPPORT MARKET GROWTH □ 134

TABLE 111 □ COMMERCIALIZED AND PIPELINE EX VIVO-BASED GENE THERAPY PRODUCTS □ 135

TABLE 112 □ EX VIVO GENE THERAPY MARKET, BY REGION, 2021-2028 (USD MILLION) □ 135

TABLE 113 □ NORTH AMERICA: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 136

TABLE 114 □ EUROPE: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 136

TABLE 115 □ ASIA PACIFIC: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 136

TABLE 116 □ LATIN AMERICA: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 137

10 □ GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION □ 138

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.1 INTRODUCTION 139

TABLE 117 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION) 139

10.2 INTRAVENOUS 139

10.2.1 EFFECTIVENESS OF INTRAVENOUS PRODUCTS TO SUPPORT MARKET GROWTH 139

TABLE 118 GENE THERAPY MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2021-2028 (USD MILLION) 140

TABLE 119 NORTH AMERICA: GENE THERAPY MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION) 140

TABLE 120 EUROPE: GENE THERAPY MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION) 141

TABLE 121 ASIA PACIFIC: GENE THERAPY MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION) 141

TABLE 122 LATIN AMERICA: GENE THERAPY MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION) 141

10.3 OTHER ROUTES OF ADMINISTRATION 142

TABLE 123 GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2021-2028 (USD MILLION) 143

TABLE 124 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION) 143

TABLE 125 EUROPE: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION) 144

TABLE 126 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION) 144

TABLE 127 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION) 144

11 GENE THERAPY MARKET, BY REGION 145

11.1 INTRODUCTION 146

TABLE 128 GENE THERAPY MARKET, BY REGION, 2021-2028 (USD MILLION) 146

11.2 NORTH AMERICA 147

FIGURE 28 NORTH AMERICA: GENE THERAPY MARKET SNAPSHOT 147

TABLE 129 NORTH AMERICA: GENE THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 148

TABLE 130 NORTH AMERICA: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION) 148

TABLE 131 NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION) 148

TABLE 132 NORTH AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 149

TABLE 133 NORTH AMERICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 149

TABLE 134 NORTH AMERICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 149

TABLE 135 NORTH AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) 150

TABLE 136 NORTH AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION) 150

TABLE 137 NORTH AMERICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION) 150

11.2.1 US 151

11.2.1.1 Growing regulatory approvals and availability of advanced treatments to drive market growth 151

TABLE 138 US FDA APPROVALS FOR GENE THERAPY PRODUCTS 151

TABLE 139 US: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION) 151

TABLE 140 US: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION) 152

TABLE 141 US: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 152

TABLE 142 US: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 152

TABLE 143 US: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 153

TABLE 144 US: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) 153

TABLE 145 US: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION) 153

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 146 US: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION) 154

11.2.2 CANADA 154

11.2.2.1 Growing gene therapy research initiatives to support growth 154

TABLE 147 CANADA: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION) 154

TABLE 148 CANADA: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION) 155

TABLE 149 CANADA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 155

TABLE 150 CANADA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 155

TABLE 151 CANADA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 156

TABLE 152 CANADA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) 156

TABLE 153 CANADA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION) 156

TABLE 154 CANADA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION) 157

11.2.3 NORTH AMERICA: RECESSION IMPACT 157

11.3 EUROPE 158

FIGURE 29 EUROPE: GENE THERAPY MARKET SNAPSHOT 159

TABLE 155 EUROPE: GENE THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 160

TABLE 156 EUROPE: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION) 160

TABLE 157 EUROPE: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION) 160

TABLE 158 EUROPE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 161

TABLE 159 EUROPE: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 161

TABLE 160 EUROPE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 161

TABLE 161 EUROPE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) 162

TABLE 162 EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION) 162

TABLE 163 EUROPE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION) 162

11.3.1 GERMANY 163

11.3.1.1 Growing collaborations in market to boost growth 163

TABLE 164 GERMANY: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION) 163

TABLE 165 GERMANY: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION) 164

TABLE 166 GERMANY: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 164

TABLE 167 GERMANY: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 164

TABLE 168 GERMANY: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 165

TABLE 169 GERMANY: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) 165

TABLE 170 GERMANY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION) 165

TABLE 171 GERMANY: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION) 166

11.3.2 UK 166

11.3.2.1 Strong government support to drive market growth 166

TABLE 172 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 166

TABLE 173 UK: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION) 167

TABLE 174 UK: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION) 167

TABLE 175 UK: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 167

TABLE 176 UK: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 168

TABLE 177 UK: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 168

TABLE 178 UK: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) 168

TABLE 179 UK: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION) 169

TABLE 180 UK: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION) 169

11.3.3 FRANCE 169

11.3.3.1 Increasing initiatives in genomic research to drive market 169

TABLE 181 FRANCE: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION) 170

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 182	FRANCE: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION)	170
TABLE 183	FRANCE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)	170
TABLE 184	FRANCE: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)	171
TABLE 185	FRANCE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)	171
TABLE 186	FRANCE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)	171
TABLE 187	FRANCE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION)	172
TABLE 188	FRANCE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)	172
11.3.4	ITALY	172
11.3.4.1	Initiatives for gene therapy development to drive growth	172
TABLE 189	ITALY: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)	173
TABLE 190	ITALY: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION)	173
TABLE 191	ITALY: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)	173
TABLE 192	ITALY: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)	174
TABLE 193	ITALY: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)	174
TABLE 194	ITALY: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)	174
TABLE 195	ITALY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION)	175
TABLE 196	ITALY: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)	175
11.3.5	SPAIN	175
11.3.5.1	Genomics initiatives and funding to support market growth	175
TABLE 197	SPAIN: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)	176
TABLE 198	SPAIN: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION)	176
TABLE 199	SPAIN: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)	176
TABLE 200	SPAIN: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)	177
TABLE 201	SPAIN: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)	177
TABLE 202	SPAIN: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)	177
TABLE 203	SPAIN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION)	178
TABLE 204	SPAIN: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)	178
11.3.6	REST OF EUROPE	178
TABLE 205	REST OF EUROPE: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)	179
TABLE 206	REST OF EUROPE: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION)	179
TABLE 207	REST OF EUROPE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)	179
TABLE 208	REST OF EUROPE: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)	180
TABLE 209	REST OF EUROPE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)	180
TABLE 210	REST OF EUROPE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)	180
TABLE 211	REST OF EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION)	181
TABLE 212	REST OF EUROPE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)	181
11.3.7	EUROPE: RECESSION IMPACT	181
11.4	ASIA PACIFIC	182
TABLE 213	ASIA PACIFIC: GENE THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	182
TABLE 214	ASIA PACIFIC: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)	182
TABLE 215	ASIA PACIFIC: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION)	183
TABLE 216	ASIA PACIFIC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)	183
TABLE 217	ASIA PACIFIC: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)	183
TABLE 218	ASIA PACIFIC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)	184
TABLE 219	ASIA PACIFIC: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)	184
TABLE 220	ASIA PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION)	184
TABLE 221	ASIA PACIFIC: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)	185

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.4.1 CHINA 185

11.4.1.1 China to dominate gene therapy market in APAC during forecast period 185

TABLE 222 CHINA: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION) 185

TABLE 223 CHINA: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION) 186

TABLE 224 CHINA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 186

TABLE 225 CHINA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 186

TABLE 226 CHINA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 187

TABLE 227 CHINA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) 187

TABLE 228 CHINA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION) 187

TABLE 229 CHINA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION) 188

11.4.2 JAPAN 188

11.4.2.1 Increasing initiatives supporting gene therapy adoption to propel market growth 188

TABLE 230 JAPAN: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION) 189

TABLE 231 JAPAN: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION) 189

TABLE 232 JAPAN: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 189

TABLE 233 JAPAN: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 190

TABLE 234 JAPAN: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 190

TABLE 235 JAPAN: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) 190

TABLE 236 JAPAN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION) 191

TABLE 237 JAPAN: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION) 191

11.4.3 INDIA 191

11.4.3.1 Increasing burden of chronic diseases to drive market growth 191

TABLE 238 INDIA: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION) 192

TABLE 239 INDIA: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION) 192

TABLE 240 INDIA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 192

TABLE 241 INDIA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 193

TABLE 242 INDIA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 193

TABLE 243 INDIA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) 193

TABLE 244 INDIA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION) 194

TABLE 245 INDIA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION) 194

11.4.4 REST OF ASIA PACIFIC 194

TABLE 246 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION) 195

TABLE 247 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION) 195

TABLE 248 REST OF ASIA PACIFIC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 195

TABLE 249 REST OF ASIA PACIFIC: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 196

TABLE 250 REST OF ASIA PACIFIC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION) 196

TABLE 251 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) 196

TABLE 252 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION) 197

TABLE 253 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION) 197

11.4.5 ASIA PACIFIC: RECESSION IMPACT 197

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Gene Therapy Market by Type (Gene silencing, Gene augmentation), Vector (Viral (Retroviral, AAV), Non-viral (Oligonucleotide)), Therapeutic Area (Neurology, Oncology), Delivery Method (In-vivo, Ex-vivo), RoA (Intravenous) & Region - Global Forecast to 2028

Market Report | 2023-10-30 | 276 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

2026-03-03

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com